Stockreport

Context Therapeutics Reports Full Year 2025 Operating and Financial Results [Yahoo! Finance]

Context Therapeutics Inc.  (CNTX) 
PDF Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected t [Read more]